Title: HIV, ART, and the ICU<br/>Author: Michael Winters<br/><a href='http://umem.org/profiles/faculty/141/'>[Click to email author]</a><hr/><p>
<strong><u>HIV, ART, and the ICU</u></strong></p>
<ul>
<li>
Though survival has dramatically improved for patients with HIV, there has been no decrease in the quantity of ICU admissions for this select patient population.</li>
<li>
One of the most common reasons for ICU admission is now adverse effects of antiretroviral therapy (ART).</li>
<li>
When managing a critically ill HIV patient in the ED or ICU, consider the following effects of ART as an etiology:
<ul>
<li>
Lactic acidosis
<ul>
<li>
Seen with nucleoside reverse transcriptase inhibitors (NRTIs): greatest risk with didanosine, stavudine, and zidovudine</li>
<li>
Presentation: fatigue, malaise, vomiting, abdominal pain, hepatomegaly</li>
<li>
Lactate often > 10 mmol/L</li>
</ul>
</li>
<li>
Abacavir hypersensitivity
<ul>
<li>
Usually within first 6 weeks of drug initiation</li>
<li>
Presentation: rash, fever, shortness of breath, vomiting, abdominal pain</li>
<li>
Can rapidly progress to cardiovascular collapse</li>
</ul>
</li>
</ul>
</li>
</ul>
<fieldset><legend>References</legend>
<p>
Tan DHS, Walmsley SL. Management of persons infected with human immunodeficiency virus requiring admission to the intensive care unit. <em>Crit Care Clin</em> 2013; 29:603-20.</p>
</fieldset>